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Abstract  Article Info 
Introduction: Nasopharyngeal carcinoma (NPC) is a type of squamous cell carcinoma that develops 
from the nasopharyngeal epithelial cells and has become one among the most popular frequent 
malignancy in the head and neck. When patients with cancer are diagnosed with COVID-19, more 
intense surveillance or treatment should be considered. 
Discussion: In the COVID 19 pandemic, Personal protection provisions should be strengthened. created 
for cancer patients and cancer survivors. To avoid the spread of COVID-19, many improvements have 
been made in the treatment of NPC patients at the Haji Adam Malik General Hospital in Medan. 
Conclusion: The management carried out on NPC patients, there are several examinations that the 
patient needs to do first in the COVID 19 pandemic at the General Hospital Haji Adam Malik Medan.  
 
 
Article history:  
Received: 7th June 2021 
Received in revised form: 17th June 2021 
Accepted: 17th June 2021 
 
Keywords: 
Nasopharyngeal carcinoma, management, 
COVID-19, Adam malik  
*Corresponding author:  
Address: Jl. Dr. Mansyur No.5, Padang Bulan, 




1.   INTRODUCTION 
Nasopharyngeal carcinoma (NPC) is a malignancy neoplasm that 
occurs in the epithelial layer of the Nasopharynx [1]. NPC is a common 
kind of head and neck cancer that develops in the pharyngeal recess 
(fossa of Rosenmüller) or the posterolateral nasopharynx [2]. In terms 
of epidemiology, etiology, a clinical attitude, reaction to treatment and 
prognosis, it differs greatly from other head and neck tumors. In 2018, 
a total of 129,000 events reported around the world, with 73,000 deaths. 
[3]. Although the NPC is unusual in the United States and Europe, it is 
endemic in Southeast Asia, North and Arctic Africa, with the endemic 
form with the infection before the old Epstein-Barr virus (EBV) and a 
not differentiated not keratinizing squamous cell carcinoma (WHO type 
III) as a prevailing histology [2, 4].  
The Covid-19 disease has become an unavoidable disease all over 
the world since February 2020, which was first from Wuhan (China) 
[5]. Serious respiratory residual syndrome, corona virus 2 (SARS-COV-
2) is guilt, although little is known about virus action modes or potential 
treatments [6]. Although in a new study showing the fact that SARS-
CoV-2 in wastewater before this date, at the same time in various 
regions, changed the understanding of the spread of the virus in Italy, 
the first confirmed case of Covid-19 in Italy was documented on 
February 21 2020, from Cutogno (Lombardei), although a recent study 
revealed the presence of SARS COV-2 in wastewater before this date, 
simultaneously in different regions, causing the understanding of virus 
proliferation in Italy to change [7 , 8].  
Positive SARS COV 2 was confirmed on a nasopharyngeal swab, 
although there is growing evidence that clinical signs of disease can occur 
even if the swab is negative, and that the presence of disease cannot be 
detected if the patient dies prematurely. Patients with COVID-19 positive 
cancer have a poor prognosis. worse than negative Covid-19 cancer patients, 
and doctors generally prove a dramatic clinical course in patients with no 
proof of infection [9, 10].  
Radiotherapy and systemic treatment are two of the most common 
treatments for nasopharyngeal carcinoma (NPC). For individuals with 
locally advanced disease, it is usually recommended to receive 
chemotheraphy nd radiotherapy on time. There is a relationship between 
delaying treatment with worsening clinical outcome [11-14].  
The treatment parameters were abstracted and summarized consisting 
of use of the rescue operation and the type of surgical approach, the method, 
the dose and the fractionation of the re-irradiation, as well as the data on 
grave (grade 3) toxicity [2]. 
 In General Hospital Haji Adam Malik Medan, management performed 
for NPC is surgery, chemotherapy and radiotheraphy. 
 
2.    MAIN TEXT 
Comprehensive risk / benefit analysis must be carried out prior to 
initiation of oncological treatment, especially in elderly patients with 
comorbidities that are candidates for the treatment of immunocontrolling 
point inhibitor. Any patient (especially if they have cancer) who has flu-like 
symptoms, severe breathing problems, or sudden kidney failure, should be 
treated as a patient with COVID-19. Even if nasopharynx smears are 
consistently negative, labor indications showing infections and radiographic 
signs of pneumonia should be treated as COVID-19. This is necessary to 
avoid underestimating the number of patients who are positive even infect 
others and increase our capacity for recognize the infection of COVID-19 
in patients with cancer [9]. 
2.1 Surgical Treatment during the COVID-19 Pandemic  
Generally corrective treatment of any cancer is not difficult to 
understand, but it is more than that for the framework of medical care, with 
doctors and other health care providers in the important part. The current 
COVID-19 pandemic is a vivid example of a situation where even 
developed countries with modern and advanced healthcare systems can 
quickly become resource-limited situations. [2].  
Severe acute respiratory syndrome caused by coronavirus 2 (SARS-
CoV-2), was first discovered in China in 2019. It's mostly seen in the 
mucosa of the upper respiratory system, notably the nasopharynx [15] [16]. 
Fourteen days are required before surgical resection of the 
nasopharynx, all patients should be isolated at home or hospitalized 
if possible to qualitatively detect nucleic acids from SARS-CoV-2, 
two real-time reverse transcription polymerase chain reaction (RT -
PCR) assays must be performed within 24 hours. Surgery can be 
performed with conventional precautions if the subject's symptoms 
are absent after 14 days of isolation or quarantine or if two different 







negative rRT-PCR results [17-19]. The medical clinic disease 
control group, in participation with microbiologists and doctor, 
should advice the further administration of patients who tried 
positive for COVID-19. It's proposed that medical procedure be 
deferred up till side effects have settled and two distinct RT -PCR 
tests have stayed no virus found in the body. According to certain 
creators, 12 weeks of hanging time is appropriate for patients 
suffering from NPC during the COVID-19 pandemic [2].  
In General Hospital Haji Adam Malik Medan, NPC patients who 
require previous surgery must have a chest x-ray and PCR swab done 
one day before surgery. If the result is positive and there are no 
symptoms, the patient must self-isolate at home for 14 days. However, 
if the patient has symptoms of COVID-19, the patient is admitted to 
the hospital for treatment. 
2.2.  Radiotherapy during the COVID-19 Pandemic  
A large number of papers in the COVID-19 pandemic advocate 
the use of hypofractionated radiation therapy to protect treatment 
capacity from understaffing, and to reduce the likelihood of infection 
of SARS-CoV-2 patients from daily hospital visits (lower fraction 
number with larger dose) [20-23].  
Despite the fact that hypofractination schemes have been 
presented for patients with head and neck cancer, according to the 
ASTRO-ESTRO Consensus Statement published in July 2020, the 
minimum currently acceptable number of fractions for curative -intent 
treatments employing IMRT is 20. [22]. However, if feasible and 
justified, referring the patient to mini-invasive endoscopic surgery 
would have the benefit of reducing the number of visits to the hospital 
and reducing the danger of cross-contamination. [2]. 
After the COVID-19 the average time spent waiting for an 
outbreak for radiotherapy was considerably greater in the case of 
patients who did not get extra chemotherapy rounds. The patient 
refused to upgrade or was unable to take extra chemotherapy sessions, 
the local hospital refused the request to admit patients who had 
previously undergone treatment at another facility and refused to 
upgrade or could not afford additional chemotherapy courses, 
according to telephone contact. Since the outbreak, the average time 
to start radiation has increased dramatically [2].  
The hospital recommends reducing intravenous infusion with 
major adverse effects for those who had begun radiation, due to 
crowding in a treatment facility and the reduced patients' immunity 
receiving radiotherapy and chemotherapy. Patients who received 
concomitant chemotherapy could have serious hematologic and 
gastrointestinal side effects [2]. 
In General Hospital Haji Adam Malik Medan, before 
radiotherapy, there is no specific procedure for the prevention of 
COVID, before radiotherapy.  
2.3. Chemotherapy during the COVID-19 Pandemic 
Concurrent chemotherapy had a lower completion rate than before [24]. 
According to Liu et al, 200 mg/m2 concomitant use of cisplatin may be the 
most effective dose for NPC patients. respond to chemotherapy for 
induction [25]. Patients who received a greater cumulative dosage of 
cisplatin had significantly better progression-free survival (PFS) and distant 
metastasis-free survival (DMFS) after three years. In NPC patients, total 
doses of greater than 300 mg/m2 cisplatin were found to be independent 
predictive variables for DMFS, disease-free survival (DFS), and overall 
survival (OS) [26]. In some patients with locally advanced NPC, however, 
multiple studies have found that IMRT alone yields similar survival rates as 
concomitant chemoradiotherapy. The impact of reducing concurrent 
platinum on patient outcomes in our group will need to be properly 
monitored in the future.  
Cancer patients were more likely than non-cancer individuals to acquire 
serious disease (39 percent versus 8%). Patients who have recently have 
undergone chemotherapy was more likely to deteriorate (75% vs 43%) [26]. 
As a result, at the site of the epidemic hypothesized that the area, delaying 
treatment or if the malignancy is stable, elective surgery may be considered 
[27]. However, for tumors with a locally advanced stage, inadequate 
dedifferentiation, such as nasopharyngeal carcinoma, we suggest that the 
patients be treated as soon as possible if the optimal treatment timeframe is 
unavailable. Replacement of less dangerous chemotherapy drugs, lowering 
of the severity of the treatment, and concurrent chemotherapy is postponed 
or skipped should all be taken into consideration for individuals undergoing 
chemotherapy to lower the likelihood of infection with COVID-19.  
It is still worth debating and researching how to choose between timely 
anticancer therapy and avoiding the risks associated with COVID-19. It may 
be possible to establish diverse tactics based on the importance of anti-tumor 
therapy [24]. 
Such as the handling of NPC with surgery and radiotherapy, 
chemotherapy during the COVID-19 pandemic at Haji Adam Malik 
Hospital in Medan, a chest X-ray and antigen swab must be carried out one 
day before chemotherapy is given. If the chest photo of a patient for 
chemotherapy shows signs of suspicion of COVID-19, chemotherapy is 
postponed, and the patient is subjected to self-isolation or treatment for 
COVID-19 first. 
 
3.   CONCLUSION 
In the management of NPC at Haji Adam Malik General Hospital, 
Medan, a chest X-ray and a PCR swab should be performed one day before 
surgery, and a chest X-ray and an antigen swab should be performed before 
chemotherapy. But in radiotherapy, there is no specific procedure for the 
prevention of COVID-19. 
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